68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
68Ga-DOTATATE Imaging in Neuroendocrine Tumors
Sponsor: Jonsson Comprehensive Cancer Center
This observational or N/A phase trial investigates Cancers Expressing Somatostatin Receptors and Carcinoid Cancer and is currently ongoing. Jonsson Comprehensive Cancer Center leads this study, which shows 9 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Aug 2020 — Jan 2021 [monthly]
No Longer Available
-
Jul 2019 — Aug 2020 [monthly]
No Longer Available
Status: Available → No Longer Available
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Available
-
Apr 2018 — Jun 2018 [monthly]
Available
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Available NA
-
Jan 2017 — Feb 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jonsson Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .